Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with these diseases. We aimed to study the impact that such alteration has on thrombotic risk and on the survival of patients with essential thrombocythemia and patients with Polycythemia Vera (PV). We studied the relationship between splenomegaly (and its grade), thrombosis and survival in 238 patients with et and 165 patients with PV followed at our center between January 1997 and May 2019.
Accurso V., Santoro M., Raso S., Contrino A.D., Casimiro P., Di Piazza F., et al. (2019). Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study. HEMATOLOGY REPORTS, 11(4), 95-97 [10.4081/hr.2019.8281].
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study
Santoro M.;Raso S.;Casimiro P.;Di Piazza F.;Perez A.;Russo A.;Siragusa S.
2019-01-01
Abstract
Splenomegaly is one of the major clinical manifestations of primary myelofibrosis and is common also in other chronic Philadelphia-negative myeloproliferative neoplasms, causing symptoms and signs and affecting quality of life of patients diagnosed with these diseases. We aimed to study the impact that such alteration has on thrombotic risk and on the survival of patients with essential thrombocythemia and patients with Polycythemia Vera (PV). We studied the relationship between splenomegaly (and its grade), thrombosis and survival in 238 patients with et and 165 patients with PV followed at our center between January 1997 and May 2019.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Splenomegaly.pdf
accesso aperto
Tipologia:
Post-print
Dimensione
330.64 kB
Formato
Adobe PDF
|
330.64 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
